ES2148174T3 - Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos. - Google Patents

Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos.

Info

Publication number
ES2148174T3
ES2148174T3 ES92907704T ES92907704T ES2148174T3 ES 2148174 T3 ES2148174 T3 ES 2148174T3 ES 92907704 T ES92907704 T ES 92907704T ES 92907704 T ES92907704 T ES 92907704T ES 2148174 T3 ES2148174 T3 ES 2148174T3
Authority
ES
Spain
Prior art keywords
receptor antagonist
opiacean
hypercinetic
modulates
movement disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92907704T
Other languages
English (en)
Inventor
Conan Kornetsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Application granted granted Critical
Publication of ES2148174T3 publication Critical patent/ES2148174T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN METODO PARA MODULAR EL ACCESO DE DISQUINESIA TARDIA EN UN SUJETO, INCLUYE EL PASO DE ADMINISTRAR AL SUJETO UN ANTAGONISTA RECEPTOR NARCOTICO CONJUNTAMENTE CON EL NEUROLEPTICO. UN METODO PARA MODULAR UN DESORDEN DE MOVIMIENTO HIPERCINETICO PSICOGENICO, GENETICO O IDIOPATICO, TAL COMO SON LAS CARACTERISTICAS DE LA ENFERMEDAD DE HUNTINGTON''S, INCLUYE EL PASO DE ADMINISTRAR AL SUJETO UN ANTAGONISTA RECEPTOR NARCOTICO.
ES92907704T 1991-02-25 1992-02-25 Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos. Expired - Lifetime ES2148174T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66054391A 1991-02-25 1991-02-25

Publications (1)

Publication Number Publication Date
ES2148174T3 true ES2148174T3 (es) 2000-10-16

Family

ID=24649948

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92907704T Expired - Lifetime ES2148174T3 (es) 1991-02-25 1992-02-25 Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos.

Country Status (9)

Country Link
US (1) US6153620A (es)
EP (1) EP0573565B1 (es)
JP (1) JPH06505747A (es)
AT (1) ATE194753T1 (es)
AU (1) AU658401B2 (es)
CA (1) CA2104229C (es)
DE (1) DE69231274T2 (es)
ES (1) ES2148174T3 (es)
WO (1) WO1992014364A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
CA2600350C (en) 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
PT2565195E (pt) 2007-03-29 2015-07-28 Wyeth Llc Antagonistas e receptor opióide periférico e respectivas utilizações
EP3064503A1 (en) 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
ES2765811T5 (es) 2007-03-29 2024-02-27 Progenics Pharm Inc Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
KR101477043B1 (ko) 2007-04-24 2014-12-29 도레이 카부시키가이샤 디스키네시아의 치료 또는 예방제
WO2009052072A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
GB2543271A (en) * 2015-10-12 2017-04-19 Lars Holger Hermann Dr Products for treating psychogenic pain disorders

Also Published As

Publication number Publication date
AU658401B2 (en) 1995-04-13
EP0573565A4 (en) 1994-03-18
CA2104229A1 (en) 1992-08-26
US6153620A (en) 2000-11-28
JPH06505747A (ja) 1994-06-30
WO1992014364A1 (en) 1992-09-03
EP0573565A1 (en) 1993-12-15
AU1456392A (en) 1992-09-15
ATE194753T1 (de) 2000-08-15
EP0573565B1 (en) 2000-07-19
DE69231274D1 (de) 2000-08-24
DE69231274T2 (de) 2000-11-30
CA2104229C (en) 1997-04-15

Similar Documents

Publication Publication Date Title
ES2148174T3 (es) Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos.
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
ATE360032T1 (de) Cystein-reiche rezeptoren-train
MX9800125A (es) Nuevas composiciones medicinales estables para generar aerosoles libres de gas propulsor.
MX9802383A (es) Derivados de pirimidina como antagonistas del receptor 5ht26.
AU7362496A (en) Dimer-selective rxr modulators and methods for their use
TW353067B (en) Isoquinolines
AU2793992A (en) Tricyclic quinoxalinediones as glutamate receptor antagonists
ITRM930561A0 (it) Classificatore purificatore polverizzatore di carbone.
EP0714295A4 (es)
EP0606804A3 (en) Neurotensin receptor marker.
ES2179529T3 (es) Compuestos biaromaticos unidos por un radical heteroetinileno, y composiciones farmaceuticas y cosmeticas que los contienen.
FR2719929B1 (fr) Dispositif de substitution d'une image artificielle présentée à un pilote d'aéronef par l'image réelle correspondante.
DE69431662D1 (de) Stabilisierte tablettenformulierung
EA199700449A1 (ru) Способ предотвращения остеопороза
NO940090D0 (no) Blanding for makrodefekt-fri sement, samt fremgangsmaate for frems tilling av denne
BR9805251A (pt) Veículo.
ES2116241B1 (es) Composicion para la obtencion de un aguardiente.
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
ES2116946B1 (es) Composicion para la obtencion de un aguardiente.
SINGH VIJAI SINGH
FR2582330B1 (fr) Systeme d'affichage, notamment pour la signalisation routiere.
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
PT746556E (pt) Compostos triciclicos com afinidade para o receptor 5-ht1a
Cannon et al. Bill Bailey

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 573565

Country of ref document: ES